In Wednesday’s session, Acumen Pharmaceuticals Inc. (NASDAQ:ABOS) marked $6.36 per share, up from $6.31 in the previous session. While Acumen Pharmaceuticals Inc. has overperformed by 0.79%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ABOS fell by -29.33%, with highs and lows ranging from $10.97 to $3.02, whereas the simple moving average jumped by 17.68% in the last 200 days.
Do You Own These 7 Inflation-Survival Stocks?
Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.
Click here to get your free copy of the report
On July 15, 2022, BTIG Research started tracking Acumen Pharmaceuticals Inc. (NASDAQ: ABOS) recommending Buy. A report published by H.C. Wainwright on June 30, 2022, Initiated its previous ‘Buy’ rating for ABOS. BofA Securities also Upgraded ABOS shares as ‘Buy’, setting a target price of $14 on the company’s shares in a report dated January 21, 2022. UBS Initiated an Buy rating on July 26, 2021, and assigned a price target of $27. Stifel initiated its ‘Buy’ rating for ABOS, as published in its report on July 26, 2021. Credit Suisse’s report from July 26, 2021 suggests a price prediction of $26 for ABOS shares, giving the stock a ‘Outperform’ rating. BofA Securities also rated the stock as ‘Neutral’.
Analysis of Acumen Pharmaceuticals Inc. (ABOS)
Acumen Pharmaceuticals Inc.’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of -18.20% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 30.60, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and ABOS has an average volume of 1.36M. On a monthly basis, the volatility of the stock is set at 8.49%, whereas on a weekly basis, it is put at 7.83%, with a gain of 3.41% over the past seven days. Furthermore, long-term investors anticipate a median target price of $15.83, showing growth from the present price of $6.36, which can serve as yet another indication of whether ABOS is worth investing in or should be passed over.
How Do You Analyze Acumen Pharmaceuticals Inc. Shares?
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 15.57%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 77.20% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
Are institutional investors increasing their holdings in ABOS shares?
The recent increase in stakes in ABOS appears to be a result of several institutional investors and hedge funds increasing their positions. Deep Track Capital LP made another increased to its shares in ABOS during the first quarter, upping its stake by 21.90%.
ABOS shares are owned by institutional investors to the tune of 77.20% at present.